Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: L Arginine Clear all
Completed Phase 2 Interventional

Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients

NCT00029731
View directory record Official record
Conditions
Anemia, Sickle Cell, Pneumonia
Interventions
Arginine hydrochloride
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
5 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Phase 2 Interventional Results available

Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

NCT01607879
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of care ADT + (HMB + arginine + glutamine), Standard of care ADT
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
60 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of L-NAME and Midodrine to Increase MAP

NCT00835224
View directory record Official record
Conditions
Orthostatic Hypotension, Spinal Cord Injury
Interventions
L-NAME, Midodrine, Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids

NCT01388764
View directory record Official record
Conditions
Dystrophinopathy, Duchenne Muscular Dystrophy, Becker's Muscular Dystrophy
Interventions
L-arginine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 11 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pathophysiology of Cardiometabolic Risk Factors in African Americans

NCT01122407
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
L-NMMA, Trimethaphan
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
30 Years to 50 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 25, 2026, 8:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Assessing the Effects of a Topically Applied Cream to Clitoral Blood Flow

NCT01085981
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%, Topical study cream, GRAS cream
Drug
Lead sponsor
East Suburban Ob Gyn
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Sep 25, 2026, 8:40 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.

NCT00280085
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
MR imaging, Glucose clamp, Arginine
Procedure · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 6, 2009 · Synced Sep 25, 2026, 8:40 PM EDT
Completed No phase listed Observational

Gyrate Atrophy of the Choroid and Retina

NCT00001166
View directory record Official record
Conditions
Gyrate Atrophy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1978 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 8:40 PM EDT
Terminated Phase 1Phase 2 Interventional

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

NCT02102022
View directory record Official record
Conditions
Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma, Gastric Cancer, Colorectal Cancer
Interventions
ADI-PEG 20 plus modified FOLFOX6
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
10
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Early Phase 1 Interventional

Oral Supplementation to Enhance Recovery Pilot Study

NCT03204266
View directory record Official record
Conditions
Malignant Neoplasms of Urinary Tract
Interventions
Arginine recovery supplement, Omega-3 Fatty Acids
Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Prevention of Low Blood Pressure in Persons With Tetraplegia

NCT00237770
View directory record Official record
Conditions
Hypotension, Spinal Cord Injury
Interventions
N-Nitro L-arginine-methylester (L-NAME), Head-up Tilt maneuver
Drug · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Early Phase 1 Interventional

Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients

NCT00047983
View directory record Official record
Conditions
Kidney Diseases
Interventions
Canola oil, Arginine, Fish oil emulsion
Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of DPP4 Inhibition on Growth Hormone Secretion

NCT01701973
View directory record Official record
Conditions
Obesity
Interventions
Sitagliptin, Pegvisomant, Placebo, L-NMMA, Exendin 9-39
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2018 · Synced Sep 25, 2026, 8:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Oral L-Citrulline and ADMA in Pregnancy

NCT00743210
View directory record Official record
Conditions
Blood Pressure
Interventions
L-citrulline, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 40 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women

NCT01186796
View directory record Official record
Conditions
Healthy
Interventions
Fulvestrant
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Sep 25, 2026, 8:40 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Estrogen and Microvascular Function

NCT06043310
View directory record Official record
Conditions
Estrogen, Cardiovascular Diseases, Microvasculature, Oral Contraceptive Use
Interventions
Nω-nitro-L-arginine methyl ester (L-NAME), Acetylcholine, Sodium Nitroprusside
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Not applicable Interventional Results available

Glutamine and Insulin Sensitivity in Type I Diabetes

NCT01467063
View directory record Official record
Conditions
Type I Diabetes Mellitus
Interventions
Glutamine, Placebo
Dietary Supplement
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 25, 2026, 8:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain Healthy Blood Pressure.

NCT06442293
View directory record Official record
Conditions
Safety Issues, Tolerance
Interventions
Treatment 1, Treatment 2, Placebo
Dietary Supplement
Lead sponsor
USANA Health Sciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 25, 2026, 8:40 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

NCT00876915
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
dalteparin injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Sacramento, California • Buffalo, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Phase 2 Interventional Results available

Trial of Aspirin and Arginine Restriction in Colorectal Cancer

NCT00578721
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Aspirin
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Not applicable Interventional

Platelet Function Analysis in Head Trauma: ASA/Plavix

NCT01534117
View directory record Official record
Conditions
Head Injury Trauma Blunt
Interventions
Platelets, DDAVP
Biological · Drug
Lead sponsor
Chang, Steve S., M.D.
Individual
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Intranasal Vasopressin Treatment in Children With Autism

NCT03204786
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder, ASD
Interventions
Vasopressin (USP) Injectable Solution [Vasostrict], Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 17 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 25, 2026, 8:40 PM EDT
Completed Phase 3 Interventional Results available

Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial

NCT04839354
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-Arginine Hydrochloride, Normal saline
Drug · Other
Lead sponsor
Claudia R. Morris
Other
Eligibility
3 Years to 21 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 25, 2026, 8:40 PM EDT